The application of a specific inhibitor of HDAC3, or BA, to induce regulatory IL-10+IgM+ PCs might therefore represent an interesting opportunity for novel treatment options and could be investigated in models of B cell-dependent inflammatory autoimmune diseases [29], e.g. models of rheumatoid arthritis [62], systemic lupus erythematosus [62], or multiple sclerosis [63]. This evidence concerns the gene HDAC3 and multiple sclerosis.